EU/3/11/900: Orphan designation for the treatment of ovarian cancer

20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate


On 27 September 2011, orphan designation (EU/3/11/900) was granted by the European Commission to Nektar Therapeutics UK Ltd, United Kingdom, for 20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate for the treatment of ovarian cancer.

Key facts

Active substance
20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate
Intended use
Treatment of ovarian cancer
Orphan designation status
EU designation number
Date of designation
Nektar Therapeutics UK Ltd
White Rose House
28A York Place
West Yorkshire LS1 2EZ
United Kingdom
Telephone: +44 113 224 5450
Telefax: +44 113 224 5498

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating